Comparison of Bioactivities of Talactoferrin and Lactoferrins From Human and Bovine Milk
Rulan Jiang
Department of Nutrition, University of California, Davis
Search for more papers by this authorXiaogu Du
Department of Nutrition, University of California, Davis
Search for more papers by this authorCorresponding Author
Bo Lönnerdal
Department of Nutrition, University of California, Davis
Address correspondence and reprint requests to Dr Bo Lönnerdal, Department of Nutrition, University of California, Davis, CA 95616 (e-mail: [email protected]).Search for more papers by this authorRulan Jiang
Department of Nutrition, University of California, Davis
Search for more papers by this authorXiaogu Du
Department of Nutrition, University of California, Davis
Search for more papers by this authorCorresponding Author
Bo Lönnerdal
Department of Nutrition, University of California, Davis
Address correspondence and reprint requests to Dr Bo Lönnerdal, Department of Nutrition, University of California, Davis, CA 95616 (e-mail: [email protected]).Search for more papers by this authorThe authors report no conflicts of interest.
ABSTRACT
Objectives:
Lactoferrin (Lf) is an iron-binding glycoprotein present in high concentration in human milk. It is a pleiotropic protein and is involved in diverse bioactivities, such as stimulation of cell proliferation and differentiation, immune competence, antimicrobial activities, anti-infection, and anticancer activities. Lf has been shown to be partly resistant to proteolysis in the gastrointestinal tract and may thus play important roles in the intestine and liver during infancy. Talactoferrin alfa (TLf) is a recombinant human Lf shown to protect against sepsis and necrotizing enterocolitis as well as cancer. Because bovine Lf (bLf) and human Lf have different amino acid composition and all 3 Lfs differ in glycosylation, they may have different functions/potency. The objective of the present study was to investigate and compare bioactivities of TLf and Lfs from human and bovine milk and thus to provide a better understanding of the bioactivities of different forms of Lf and their potential applications.
Methods:
In the present study, Caco-2 and C3A cells were used as intestine and liver models to evaluate internalization of Lfs by intestine and liver cells, effects of Lfs on cell proliferation and differentiation, growth of enteropathogenic Escherichia coli (EPEC), chemokine (C-C motif) ligand 20 (CCL20) secretion, and transforming growth factor (TGF)-β1 expression. In addition, HT-29 cells were used as a colon cancer cell model to examine the effects of Lfs on apoptosis.
Results:
All Lfs significantly enhanced cell proliferation and differentiation, apoptosis, CCL20 secretion, and TGF-β1 expression. They also markedly suppressed growth of EPEC. Compared with bLf, TLf showed stronger effects on suppression of EPEC growth and enhancement of TGF-β1 secretion, whereas bLf exhibited more potent effects on cell differentiation, apoptosis, and CCL20 secretion.
Conclusions:
Our results demonstrate that TLf has several bioactivities similar to human Lf and bLf from milk and may play critical roles in immune and intestinal development in infants as well as having anti-cancer activities in adults. TLf and bLf may be used for different applications owing to their various potencies. TLf may preferentially be used for anti-bacterial applications, whereas bLf may be used for cancer therapy because it exhibits stronger effects on CCL20 secretion, cell differentiation, and apoptosis.
REFERENCES
- 1Lönnerdal B, Iyer S. Lactoferrin: molecular structure and biological function. Annu Rev Nutr 1995; 93–110.
- 2Vogel HJ. Lactoferrin, a bird's eye view. Biochem Cell Biol 2012; 90: 233–244.
- 3Lönnerdal B, Jiang R, Du X. Bovine lactoferrin can be taken up by the human intestinal lactoferrin receptor and exert bioactivities. J Pediatr Gastroenterol Nutr 2011; 53: 606–614.
- 4Manzoni P, Rinaldi M, Cattani S, et al. Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. JAMA 2009; 302: 1421–1428.
- 5Ward PP, Piddington CS, Cunningham GA, et al. A system for production of commercial quantities of human lactoferrin: a broad spectrum natural antibiotic. Biotechnology (N Y) 1995; 13: 498–503.
- 6Sun XL, Baker HM, Shewry SC, et al. Structure of recombinant human lactoferrin expressed in Aspergillus awamori. Acta Crystallogr D Biol Crystallogr 1999; 55: 403–407.
- 7Guntupalli K, Dean N, Morris PE, et al. A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis. Crit Care Med 2013; 41: 706–716.
- 8Digumarti R, Wang Y, Raman G, et al. A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer. J Thorac Oncol 2011; 6: 1098–1103.
- 9Parikh PM, Vaid A, Advani SH, et al. Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy. J Clin Oncol 2011; 29: 4129–4136.
- 10Almond RJ, Flanagan BF, Antonopoulos A, et al. Differential immunogenicity and allergenicity of native and recombinant human lactoferrins: role of glycosylation. Eur J Immunol 2012; 43: 170–181.
- 11Barboza M, Pinzon J, Wickramasinghe S, et al. Glycosylation of human milk lactoferrin exhibits dynamic changes during early lactation enhancing its role in pathogenic bacteria-host interactions. Mol Cell Proteomics 2012; 11: M111 015248.
- 12Davidson LA, Lönnerdal B. Persistence of human milk proteins in the breast-fed infant. Acta Paediatr Scand 1987; 76: 733–740.
- 13Suzuki YA, Shin K, Lönnerdal B. Molecular cloning and functional expression of a human intestinal lactoferrin receptor. Biochemistry 2001; 40: 15771–15779.
- 14Appelmelk BJ, An YQ, Geerts M, et al. Lactoferrin is a lipid A-binding protein. Infect Immun 1994; 62: 2628–2632.
- 15Nuijens JH, van Berkel PH, Geerts ME, et al. Characterization of recombinant human lactoferrin secreted in milk of transgenic mice. J Biol Chem 1997; 272: 8802–8807.
- 16Alpers DH, Mahmood A, Engle M, et al. The secretion of intestinal alkaline phosphatase (IAP) from the enterocyte. J Gastroenterol 1994; 29 (suppl 7): 63–67.
- 17Benoit YD, Pare F, Francoeur C, et al. Cooperation between HNF-1 alpha, Cdx2, and GATA-4 in initiating an enterocytic differencetiation program in a normal humanintestinal epithelial progenitor cell line. Am J Physiol Gastrointest Liver Physiol 2010; 298: G504–G517.
- 18Lopez V, Kelleher SL, Lönnerdal B. Lactoferrin receptor mediates apo- but not holo-lactoferrin internalization via clathrin-mediated endocytosis in trophoblasts. Biochem J 2008; 411: 271–278.
- 19Elass-Rochard E, Legrand D, Salmon V, et al. Lactoferrin inhibits the endotoxin interaction with CD14 by competition with the lipopolysaccharide-binding protein. Infect Immun 1998; 66: 486–491.
- 20Grossmann JG, Neu M, Pantos E, et al. X-ray solution scattering reveals conformational changes upon iron uptake in lactoferrin, serum and ovo-transferrins. J Mol Biol 1992; 225: 811–819.
- 21Buccigrossi V, de Marco G, Bruzzese E, et al. Lactoferrin induces concentration-dependent functional modulation of intestinal proliferation and differentiation. Pediatr Res 2007; 61: 410–414.
- 22Kim CW, Son KN, Choi SY, et al. Human lactoferrin upregulates expression of KDR/Flk-1 and stimulates VEGF-A-mediated endothelial cell proliferation and migration. FEBS Lett 2006; 580: 4332–4336.
- 23Tang L, Cui T, Wu JJ, et al. A rice-derived recombinant human lactoferrin stimulates fibroblast proliferation, migration, and sustains cell survival. Wound Repair Regen 2010; 18: 123–131.
- 24Sambuy Y, De Angelis I, Ranaldi G, et al. The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics. Cell Biol Toxicol 2005; 21: 1–26.
- 25Tsuda H, Sekine K, Nakamura J, et al. Inhibition of azoxymethane initiated colon tumor and aberrant crypt foci development by bovine lactoferrin administration in F344 rats. Adv Exp Med Biol 1998; 443: 273–284.
- 26Kim MJ, Kim YJ, Park HJ, et al. Apoptotic effect of red wine polyphenols on human colon cancer SNU-C4 cells. Food Chem Toxicol 2006; 44: 898–902.
- 27Gouyer V, Fontaine D, Dumont P, et al. Autocrine induction of invasion and metastasis by tumor-associated trypsin inhibitor in human colon cancer cells. Oncogene 2008; 27: 4024–4033.
- 28Schutyser E, Struyf S, Van Damme J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev 2003; 14: 409–426.
- 29Rubie C, Oliveira V, Kempf K, et al. Involvement of chemokine receptor CCR6 in colorectal cancer metastasis. Tumour Biol 2006; 27: 166–174.
- 30Skeen VR, Paterson I, Paraskeva C, et al. TGF-beta1 signalling, connecting aberrant inflammation and colorectal tumorigenesis. Curr Pharm Des 2012; 18: 3874–3888.
- 31Francis N, Wong SH, Hampson P, et al. Lactoferrin inhibits neutrophil apoptosis via blockade of proximal apoptotic signaling events. Biochim Biophys Acta 2011; 1813: 1822–1826.
- 32Amini AA, Nair LS. Evaluation of the bioactivity of recombinant human lactoferrins toward murine osteoblast-like cells for bone tissue engineering. Tissue Eng Part A 2013; 19: 1047–1055.
- 33He J, Furmanski P. Sequence specificity and transcriptional activation in the binding of lactoferrin to DNA. Nature 1995; 373: 721–724.
- 34Son KN, Park J, Chung CK, et al. Human lactoferrin activates transcription of IL-1beta gene in mammalian cells. Biochem Biophys Res Commun 2002; 290: 236–241.
- 35Nakajima K, Kanno Y, Nakamura M, et al. Bovine milk lactoferrin induces synthesis of the angiogenic factors VEGF and FGF2 in osteoblasts via the p44/p42 MAP kinase pathway. Biometals 2011; 24: 847–856.
- 36Hayes TG, Falchook GF, Varadhachary GR, et al. Phase I trial of oral talactoferrin alfa in refractory solid tumors. Invest New Drugs 2006; 24: 233–240.
- 37Troost FJ, Steijns J, Saris WH, et al. Gastric digestion of bovine lactoferrin in vivo in adults. J Nutr 2001; 131: 2101–2104.
- 38Troost FJ, Saris WH, Brummer RJ. Orally ingested human lactoferrin is digested and secreted in the upper gastrointestinal tract in vivo in women with ileostomies. J Nutr 2002; 132: 2597–2600.
- 39Legrand D, Pierce A, Elass E, et al. Lactoferrin structure and functions. Adv Exp Med Biol 2008; 606: 163–194.
- 40Suzuki YA, Lopez V, Lönnerdal B. Mammalian lactoferrin receptors: structure and function. Cell Mol Life Sci 2005; 62: 2560–2575.
- 41Ziere GJ, Bijsterbosch MK, van Berkel TJ. Removal of 14 N-terminal amino acids of lactoferrin enhances its affinity for parenchymal liver cells and potentiates the inhibition of beta- very low density lipoprotein binding. J Biol Chem 1993; 268: 27069–27075.
- 42Bennatt DJ, McAbee DD. Identification and isolation of a 45-kDa calcium-dependent lactoferrin receptor from rat hepatocytes. Biochemistry 1997; 36: 8359–8366.
- 43Naot D, Chhana A, Matthews BG, et al. Molecular mechanisms involved in the mitogenic effect of lactoferrin in osteoblasts. Bone 2011; 49: 217–224.
- 44Tang L, Wu JJ, Ma Q, et al. Human lactoferrin stimulates skin keratinocyte function and wound re-epithelialization. Br J Dermatol 2010; 163: 38–47.
- 45Jiang R, Lopez V, Kelleher SL, et al. Apo- and holo-lactoferrin are both internalized by lactoferrin receptor via clathrin-mediated endocytosis but differentially affect ERK-signaling and cell proliferation in Caco-2 cells. J Cell Physiol 2011; 226: 3022–3031.
- 46Zimecki M, Mazurier J, Spik G, et al. Human lactoferrin induces phenotypic and functional changes in murine splenic B cells. Immunology 1995; 86: 122–127.
- 47Takayama Y, Mizumachi K. Effect of lactoferrin-embedded collagen membrane on osteogenic differentiation of human osteoblast-like cells. J Biosci Bioeng 2009; 107: 191–195.
- 48Yagi M, Suzuki N, Takayama T, et al. Effects of lactoferrin on the differentiation of pluripotent mesenchymal cells. Cell Biol Int 2009; 33: 283–289.
- 49Ying X, Cheng S, Wang W, et al. Effect of lactoferrin on osteogenic differentiation of human adipose stem cells. Int Orthop 2012; 36: 647–653.
- 50Drozdowski LA, Clandinin T, Thomson AB. Ontogeny, growth and development of the small intestine: understanding pediatric gastroenterology. World J Gastroenterol 2010; 16: 787–799.
- 51Iigo M, Alexander DB, Long N, et al. Anticarcinogenesis pathways activated by bovine lactoferrin in the murine small intestine. Biochimie 2009; 91: 86–101.
- 52Duarte DC, Nicolau A, Teixeira JA, et al. The effect of bovine milk lactoferrin on human breast cancer cell lines. J Dairy Sci 2011; 94: 66–76.
- 53Wang J, Li Q, Ou Y, et al. Inhibition of tumor growth by recombinant adenovirus containing human lactoferrin through inducing tumor cell apoptosis in mice bearing EMT6 breast cancer. Arch Pharm Res 2011; 34: 987–995.
- 54Lee SH, Hwang HM, Pyo CW, et al. E2F1-directed activation of Bcl-2 is correlated with lactoferrin-induced apoptosis in Jurkat leukemia T lymphocytes. Biometals 2010; 23: 507–514.
- 55Xu XX, Jiang HR, Li HB, et al. Apoptosis of stomach cancer cell SGC-7901 and regulation of Akt signaling way induced by bovine lactoferrin. J Dairy Sci 2010; 93: 2344–2350.
- 56Sherman MP, Petrak K. Lactoferrin-enhanced anoikis: a defense against neonatal necrotizing enterocolitis. Med Hypotheses 2005; 65: 478–482.
- 57Ramalingam S, Crawford J, Chang A, et al. Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). Ann Oncol 2013; 24: 2875–2880.
- 58Riess JW, Bhattacharya N, Blenman KR, et al. Immune correlates of talactoferrin alfa in biopsied tumor of relapsed/refractory metastatic non-small cell lung cancer patients. Immunopharmacol Immunotoxicol 2014; 36: 182–186.
- 59Kaper JB, Nataro JP, Mobley HL. Pathogenic Escherichia coli. Nat Rev Microbiol 2004; 2: 123–140.
- 60Chen HD, Frankel G. Enteropathogenic Escherichia coli: unravelling pathogenesis. FEMS Microbiol Rev 2005; 29: 83–98.
- 61Edde L, Hipolito RB, Hwang FF, et al. Lactoferrin protects neonatal rats from gut-related systemic infection. Am J Physiol Gastrointest Liver Physiol 2001; 281: G1140–G1150.
- 62McCulloh R, Opal SM. Human recombinant lactoferrin for sepsis: too good to be true? Crit Care Med 2013; 41: 908–909.
- 63Sherman MP. New concepts of microbial translocation in the neonatal intestine: mechanisms and prevention. Clin Perinatol 2010; 37: 565–579.
- 64Spadaro M, Montone M, Arigoni M, et al. Recombinant human lactoferrin induces human and mouse dendritic cell maturation via Toll-like receptors 2 and 4. FASEB J 2014; 28: 416–429.
- 65Wynn JL, Levy O. Role of innate host defenses in susceptibility to early-onset neonatal sepsis. Clin Perinatol 2010; 37: 307–337.
- 66Adams-Chapman I. Long-term impact of infection on the preterm neonate. Semin Perinatol 2012; 36: 462–470.
- 67Leitch EC, Willcox MD. Elucidation of the antistaphylococcal action of lactoferrin and lysozyme. J Med Microbiol 1999; 48: 867–871.
- 68Gonzalez-Chavez SA, Arevalo-Gallegos S, Rascon-Cruz Q. Lactoferrin: structure, function and applications. Int J Antimicrob Agents 2009; 33: 301e1–8.
- 69Ellison RT 3rd, Giehl TJ. Killing of gram-negative bacteria by lactoferrin and lysozyme. J Clin Invest 1991; 88: 1080–1091.
- 70Pammi M, Abrams SA. Oral lactoferrin for the prevention of sepsis and necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev 2011; CD007137.
- 71Venkatesh MP, Pham D, Kong L, et al. Prophylaxis with lactoferrin, a novel antimicrobial agent, in a neonatal rat model of coinfection. Adv Ther 2007; 24: 941–954.
- 72Baba M, Imai T, Nishimura M, et al. Identification of CCR6, the specific receptor for a novel lymphocyte-directed CC chemokine LARC. J Biol Chem 1997; 272: 14893–14898.
- 73Izadpanah A, Dwinell MB, Eckmann L, et al. Regulated MIP-3alpha/CCL20 production by human intestinal epithelium: mechanism for modulating mucosal immunity. Am J Physiol Gastrointest Liver Physiol 2001; 280: G710–G719.
- 74Uchida H, Iwashita Y, Sasaki A, et al. Chemokine receptor CCR6 as a prognostic factor after hepatic resection for hepatocellular carcinoma. J Gastroenterol Hepatol 2006; 21: 161–168.
- 75Ito T, Carson WFT, Cavassani KA, et al. CCR6 as a mediator of immunity in the lung and gut. Exp Cell Res 2011; 317: 613–619.
- 76Williams IR. CCR6 and CCL20: partners in intestinal immunity and lymphorganogenesis. Ann N Y Acad Sci 2006; 1072: 52–61.
- 77Yang D, Chen Q, Hoover DM, et al. Many chemokines including CCL20/MIP-3alpha display antimicrobial activity. J Leukoc Biol 2003; 74: 448–455.
- 78Wolf M, Moser B. Antimicrobial activities of chemokines: not just a side-effect? Front Immunol 2012; 3: 213.
- 79Kitagawa Y, Kikuchi S, Arita Y, et al. Inhibition of CCL20 increases mortality in models of mouse sepsis with intestinal apoptosis. Surgery 2013; 154: 78–88.
- 80Bell D, Chomarat P, Broyles D, et al. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med 1999; 190: 1417–1426.
- 81Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539–545.
- 82Spadaro M, Caorsi C, Ceruti P, et al. Lactoferrin, a major defense protein of innate immunity, is a novel maturation factor for human dendritic cells. FASEB J 2008; 22: 2747–2757.
- 83Ghadjar P, Rubie C, Aebersold DM, et al. The chemokine CCL20 and its receptor CCR6 in human malignancy with focus on colorectal cancer. Int J Cancer 2009; 125: 741–745.
- 84Ikushima H, Miyazono K. TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer 2010; 10: 415–424.
- 85Roberts AB. Molecular and cell biology of TGF-beta. Miner Electrolyte Metab 1998; 24: 111–119.
- 86Travis MA, Reizis B, Melton AC, et al. Loss of integrin alpha(v)beta8 on dendritic cells causes autoimmunity and colitis in mice. Nature 2007; 449: 361–365.
- 87Yamada Y, Mashima H, Sakai T, et al. Functional roles of TGF-beta1 in intestinal epithelial cells through Smad-dependent and non-Smad pathways. Dig Dis Sci 2013; 58: 1207–1217.
- 88Hague A, Bracey TS, Hicks DJ, et al. Decreased levels of p26-Bcl-2, but not p30 phosphorylated Bcl-2, precede TGFbeta1-induced apoptosis in colorectal adenoma cells. Carcinogenesis 1998; 19: 1691–1695.
- 89Shima Y, Nakao K, Nakashima T, et al. Activation of caspase-8 in transforming growth factor-beta-induced apoptosis of human hepatoma cells. Hepatology 1999; 30: 1215–1222.